is a long-lasting autoimmune disease, which is characterized by patches of abnormal skin. It is a non-curable disease; however, treatment options will help to control the disease for many patients. This study provides information on the current reimbursement situation with biological agents in various European countries, which are part of the treatment plans of middle to severe Psoriasis. MethOds: The international HTA database Prismaccess® includes all decisions by market access authorities, among others from England, Scotland, France, Germany and Sweden. All decisions on therapies for Psoriasis launched in these countries since 2011 were considered for a systematic reimbursement analysis. Results: In total, there were 57 decisions considered. France with the Transparency Committee is leading with 22 decisions, followed by Sweden's TLV with 12, the Scottish SMC with 10 and German's G-BA and IQWiG with 2 and UK's NICE with 4 recommendations. The level of added benefit differs in extent and between countries. In France, 2 subgroups obtained a ASMRs of IV, while majority reached an ASMR V, which means no added benefit. SMC recommended 2 therapies, 7 as restricted and did 1 not recommended; TLV rated 8 as recommended and 4 as restricted. NICE evaluated 3 drugs as recommended and 1 as not accepted. In Germany G-BA/IQWiG evaluated 4 drugs: 2 therapies received no added benefit and 2 received an added benefit in at least one subgroup. Overall, different decisions of the respective HTA bodies could be identified for 9 treatments. They differ in appropriate comparator therapy, patient population or economic data. cOnclusiOns: The analysis showed differences in the assessment of Psoriasis drugs between different market access authorities in Europe. Reasons vary hugely and need to be taken into account in future market access submissions. SY3 How will PaYerS Manage tHe CoSt of new, advanCed BiologiC and onCologiC agentS aS tHeraPY areaS BeCoMe Crowded witH drugS witH SiMilar MeCHaniSMS of aCtion?

No abstract

No abstract